Protocol Ledger

NCT05518578 · Phase II · RECRUITING

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Interventional Phase II clinical trial protocol NCT05518578 sponsored by Supernus Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-07 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05518578
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05518578
Protocol FieldVerified Registry Value
NCT IdentifierNCT05518578
Consolidated Lead SponsorSupernus Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2023-02-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05518578
Hospital Research SiteLocationSite Profile
Box Hill HospitalBox Hill, AustraliaOpen Hospital Dossier ->
The Alfred HospitalMelbourne, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI